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ABSTRACT
Background: Ventilator-associated pneumonia (VAP)
affects up to 20% of patients admitted to intensive care
units (ICU). It is associated with increased morbidity,
mortality and healthcare costs. Despite published
guidelines, variability in diagnosis and management
exists, the extent of which remains unclear. We sought
to characterise consultant opinions surrounding
diagnostic and management practice for VAP in the UK.
Methods: An online survey was sent to all consultant
members of the UK Intensive Care Society (n=∼1500).
Data were collected regarding respondents’ individual
practice in the investigation and management of
suspected VAP including use of diagnostic criteria,
microbiological sampling, chest X-ray (CXR),
bronchoscopy and antibiotic treatments.
Results: 339 (23%) responses were received from a
broadly representative spectrum of ICU consultants. All
respondents indicated that microbiological confirmation
should be sought, the majority (57.8%) stating they
would take an endotracheal aspirate prior to starting
empirical antibiotics. Microbiology reporting services
were described as qualitative only by 29.7%. Only 17%
of respondents had access to routine reporting of CXRs
by a radiologist. Little consensus exists regarding
technique for bronchoalveolar lavage (BAL) with the
reported volume of saline used ranging from 5 to
500 mL. 24.5% of consultants felt inadequately trained
in bronchoscopy.
Conclusions: There is wide variability in the approach
to diagnosis and management of VAP among UK
consultants. Such variability challenges the reliability of
the diagnosis of VAP and its reported incidence as a
performance indicator in healthcare systems. The data
presented suggest increased radiological and
microbiological support, and standardisation of BAL
technique, might improve this situation.
INTRODUCTION
Ventilator-associated pneumonia (VAP) is a
common nosocomial infection affecting up to
20% of patients admitted to intensive care
units (ICUs).1–3 VAP is associated with a 2–7-
fold increased risk of death4 5; although the
actual attributable mortality of VAP has proven
difficult to determine with a wide range of
estimates reported.1–3 6–8 Furthermore, VAP is
associated with excess morbidity and health-
care costs, increasing hospital length of stay by
an average of 4–9 days.1 5 6 Despite the intro-
duction of preventive measures aimed at redu-
cing VAP rates it remains prevalent within
ICUs. This has led to the incidence of VAP
being adopted as a performance indicator in
some healthcare systems. In turn, this has
drawn further attention to the significant chal-
lenges the condition presents in terms of diag-
nosis and management. The lack of consensus
as to diagnostic criteria or the ‘gold standard’
diagnostic test has hampered research devel-
opment over recent years and more recently
has led to discrepancies in clinical VAP rates
and reported surveillance rates.9
Although guidelines have been pub-
lished,10–12 variability in the approach to diag-
nostic procedures and management of VAP
exists and is poorly defined. We therefore
sought to characterise consultant opinion sur-
rounding diagnostic and management prac-
tice for VAP in the UK.
METHODS
All consultant members of the UK Intensive
Care Society were invited to take part in an
online survey. A survey tool was developed
KEY MESSAGES
▸ Despite guidelines, marked variation in the diagno-
sis and management of ventilator-associated
pneumonia (VAP) continues to exist within the UK.
▸ Until a consensus approach is reached the use
of VAP rates as a performance indicator in
healthcare systems is unreliable.
▸ Increased radiological and microbiological support
may improve the diagnosis of VAP.
▸ Better training in the performance of bronchoal-
veolar lavage (BAL) may lead to increased deliv-
ery of high-quality BAL and improved diagnosis
of VAP.
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and piloted in a local ICU prior to distribution nationally.
The survey collected data regarding demographics of the
respondents’ place of work and their individual practice
in the investigation and management of suspected VAP
including use of diagnostic criteria, microbiological sam-
pling, chest X-ray (CXR), bronchoscopy and bronchoal-
veolar lavage (BAL) and antibiotic treatments.
The survey was hosted by the Survey Monkey website
(http://www.surveymonkey.com). An email inviting par-
ticipation was sent to all consultant members of the UK
Intensive Care Society. All responses were anonymous in
terms of the individual and their place of work. Both
quantitative and qualitative data were collected for ana-
lysis. Reminder emails were sent to all consultant
members 2 and 10 weeks after the initial invitation to
encourage participation.
The survey questions are summarised in the online
supplementary section.
Descriptive statistical data are presented as mean
(SD), median (IQR) and percentages. Correlations were
tested using Spearman’s rank correlation coefficient.
RESULTS
Demographic data
Responses were received from 339 of approximately 1500
consultants surveyed (23%). Only 266 respondents com-
pleted the survey in full (266/339=78.4%). Consultant
experience in intensive care medicine varied with a
median number of years practising of 14 (range 1–35).
Respondents reported a median number of staffed level 3
beds (beds where patients may receive advanced respira-
tory support) per unit of 8 (range 2–40, IQR 6–12), with
an average of 69.5% (SD±17) of beds estimated to be
occupied by intubated, mechanically ventilated patients
at any one time. There was a wide case mix reported
within the units. Mean case load is illustrated in figure 1.
Responses were received from 28 consultants (8.3%)
working in specialist units (21 specialist cardiothoracic
and 7 specialist neurology/neurosurgery) where 100% of
patients were from the relevant specialty.
Diagnosis
Clinical criteria
Respondents were asked to list criteria they considered to
be mandatory for a diagnosis of VAP. A wide variety of
responses were received. When respondents’ answers were
compared with the criteria set out in published guidelines
for the diagnosis of VAP 60.6% (163/269) of respondents
matched the Canadian Thoracic Society guidelines, 55.3%
(149/269) the American Thoracic Society guidelines,
49.1% (132/269) the HELICS (Hospitals in Europe for
Infection Control through Surveillance) criteria and
28.3% (76/269) the Guidelines from the British Society of
Antimicrobial Therapy (figure 2). In total 33.1% (89/269)
of respondents did not include CXR appearances within
the list of criteria they considered mandatory for a diagno-
sis of VAP.
Microbiological sampling and bronchoscopic technique
Respondents were asked to choose one option (from
those shown in figure 3) which best reflected their
current practice when suspecting a diagnosis of VAP. All
respondents indicated that some form of microbio-
logical confirmation should be sought with the majority
of consultants, 58% (156/269) indicating that they
would take an endotracheal aspirate (ETA) prior to start-
ing empirical antibiotics.
In terms of experience in bronchoscopy 74.1%
(200/270) of respondents reported that they personally
Figure 1 Mean case load within
respondent’s intensive care unit.
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undertook bronchoscopy within the ICU. Only 27.1%
(73/269) performed bronchoscopic sampling in cases of
suspected VAP. The estimated number of bronchosco-
pies performed per month per unit varied widely with a
rate per level 3 bed of 0–5.8 (mean 0.89, SD±0.82).
There was little consensus in the reported technique for
bronchoscopic sampling. The reported volume of saline
used to perform a BAL ranged from 5 to 500 mL
(median 20 mL, IQR 20–40) with only 9.6% (20/208) of
respondents instilling>100 mL. In terms of the sampling
site respondents were asked to identify which lobe/
segment they would lavage in a patient with diffuse bilat-
eral shadowing on CXR. The most frequently cited loca-
tions were both lower lobes (27.3%, 57/209), right lower
lobe (16.3%, 34/209), or the right middle lobe (13.4%,
28/209), while 22 respondents (10.9%) stated that they
would lavage all lobes. 24.5% (49/200) of respondents
who perform diagnostic bronchoscopy felt that they
were not adequately trained in the procedure with 9.5%
(19/200) stating they had received no training at all.
The level of confidence in performing BAL was
reported to be high, however, with a mean score of 8.3/
10 (SD±1.7 on a linear scale of 0–10 where 0 repre-
sented no confidence and 10 represented 100% confi-
dence). This compared to confidence levels of 4.7/10
(SD±2.6) for recognition of a tumour, 1.8/10 (SD±3.0)
for endobronchial biopsy and 8.4/10 (SD±1.5) for clear-
ance of impacted mucus. There was no significant cor-
relation between years of experience in intensive care
medicine and confidence in performing BAL (rs=0.013,
p=0.85).
Data were collected about the availability of qualitative
and quantitative microbiology services within respondents’
hospitals (figure 4). Microbiology departments were said
to issue qualitative reports only by 29.7% (80/269) of
respondents, as compared with semiquantitative reporting
(37.9%, 102/269) and quantitative reporting (18.6%,
50/269). 13.8% (37/269) of respondents were unsure of
the nature of microbiology services available within their
hospital.
Chest X-ray
Data were gathered in relation to the frequency of, and
indications for, CXR in ventilated patients on ICU. In
total, 76.7% (204/266) stated they only perform CXRs
on ventilated patients when considered clinically indi-
cated, 13.5% (36/266) reported requesting a CXR on
patients routinely every 3–4 days, 5.3% (14/266) every
other day, 2.6% (7/266) once a week and 1.9% (5/266)
on a daily basis. The features reported as most likely to
be considered an indication for a CXR in a ventilated
patient were new signs on auscultation and a rise in
required inspired oxygen concentration. These were fol-
lowed in order of likelihood by; the presence of new
purulent secretions, a new temperature, a new or
increasing inotrope requirement, and a new rise in
white cell count (WCC).
Data were collected regarding the level of reporting of
CXRs on the ICU (figure 5). A total of 46.2% (123/266)
stated that on their unit CXRs are reported by ICU staff,
with interesting CXRs discussed with a radiologist in
person or at an X-ray meeting (selected reporting).
18.8% (50/266) reported that CXR interpretation was
done entirely by ICU staff (no reporting), 18.1% (48/
266) by a radiologist when specifically requested to do so
(reporting by request) and 16.9% (45/266) stated all
Figure 2 Recognised criteria for diagnosis of ventilator-associated pneumonia (CXR, chest X-ray).
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CXRs on their unit were reported by a radiologist (full
reporting).
Respondents were asked to indicate their level of con-
fidence in interpreting CXRs performed on intubated,
mechanically ventilated patients. The mean score was
8.4/10 (SD±1.1) on a linear scale of 0–10 where 0 repre-
sented no confidence and 10 represented 100% confi-
dence. There was no significant correlation between
confidence in interpreting CXRs and years of experi-
ence in ICU (rs=0.079, p=0.199).
Treatment
Pathogens
Respondents were asked to list what they considered to be
the commonest organism causing VAP within their unit.
The organism most frequently cited was Pseudomonas
aeruginosa (30.1%, 81/269), followed by Enterobacteriaceae
(35.7%, 96/269; including ‘coliforms’ (20.8%, 56/269),
Escherichia coli (10.8%, 29/269), Klebsiella spp (3.3%, 9/269)
and Enterobacter cloacae (0.7%, 2/269)) and methicillin-
sensitive Staphylococcus aureus (10.8%, 29/269). Fungal and
viral infections were mentioned infrequently (<1%).
Antibiotic therapy
A single agent antibiotic regimen was identified in the
majority of cases as being the usual empirical antibiotic
therapy (78.8%, 212/269). Piperacillin-tazobactam was
the most frequently reported antibiotic, (69.9% (188/
269) of respondents) followed by meropenem (24.2%,
65/269). Forty-three different single or double agent
antibiotic regimens were listed as being usually pre-
scribed empirical antibiotic therapy in cases of suspected
VAP. The 15 most frequently cited antibiotic regimens
are illustrated in figure 6. Median reported duration of
antibiotic therapy for the treatment of VAP was 6 days
(IQR 5–7). Prescribed courses ranged from 3 to 14 days
in duration.
Figure 3 Current practice when suspecting a diagnosis of
ventilator-associated pneumonia (abx, antibiotics; ETA,
endotracheal aspirate; BAL, bronchoalveolar lavage; PSB,
protected specimen brush).
Figure 5 Level of reporting of chest X-rays on the intensive
care unit.
Figure 4 Availability of microbiology services within
respondents’ hospitals.
Figure 6 Reported empirical antibiotic selection in cases of
suspected ventilator-associated pneumonia.
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DISCUSSION
The results of this study show that there continues to be
wide variation in practice in relation to the investigation,
diagnosis and treatment of VAP in the UK. Although the
overall response rate was low, comparison with a
PubMed search of surveys of ICU consultants over the
past 10 years showed that responses were received from a
broadly representative spectrum of consultants in terms
of clinical experience and case load. This suggests that
the data gathered are generally reflective of current UK
consultant practice.13–16
It is well recognised that diagnosis of VAP is extremely
difficult on clinical grounds alone.3 17 There is significant
overlap in the signs and symptoms associated with VAP
and many other conditions affecting patients on ICU.
Clinical criteria such as a new or persistent alveolar infil-
trates on CXR in association with purulent tracheal secre-
tions, increasing oxygen requirements, temperature
>38°C and WCC >10 000/mm3 or <4000/mm3 have been
incorporated into guidelines and clinical scoring systems
to aid in the diagnosis.10 12 17 Despite such guidance sur-
rounding the use of clinical criteria however, there was
little consensus among respondents regarding those cri-
teria considered mandatory for diagnosis, with only
60.6% of respondents listing criteria fulfilling at least one
of the national guideline definitions for VAP based on
clinical criteria. A total of 33.1% (89/269) of respondents
did not consider a CXR to be required which is contrary
to guideline recommendations stating that all patients
with suspected VAP should have a CXR performed to
look for the presence of new infiltrates.10–12
The radiological diagnosis of VAP is also challenging
with low diagnostic sensitivity and specificity of CXR
signs in ventilated patients leading to difficulties in inter-
pretation. The only sign to correlate well with the pres-
ence of pneumonia is the air bronchogram but even the
specificity of this is reduced when coexistent acute
respiratory distress syndrome is present.18 We are
unaware of data comparing the diagnostic accuracy of
radiologists and intensivists in the setting of suspected
VAP, however data from the pneumonia literature gener-
ally suggests that interobserver variability in CXRs is
high, and that radiologists probably provide greater diag-
nostic accuracy.19 20 Despite this only 16.9% of respon-
dents had access to routine reporting of CXRs by a
radiologist and confidence in interpreting CXRs was
reported to be high with a mean score of 8.4/10.
In terms of microbiological sampling, the majority of
respondents reported that their usual practice was to
take an ETA for culture prior to starting empirical anti-
biotics. Colonisation of the proximal airways is common
in intubated patients. Non-quantitative culture of patho-
gens from ETAs commonly reflects such colonisation
rather than a pneumonic process. Qualitative ETAs are
known to have high sensitivity and low specificity for the
diagnosis of VAP, so while they may have a role in exclud-
ing VAP, their use for diagnostic purposes is associated
with a high rate of false positives and excessive use of
unnecessary antibiotics.3 10 21 The suggestion that
approximately 50% of respondents do not have access to
quantitative or semiquantitative culture in decision-
making may therefore have important consequences.
Although there are few studies directly comparing the
use of qualitative versus quantitative ETA, a diagnostic
cut-off of >106 colony-forming units (CFU) per millilitre
has been shown to significantly increase the specificity
of ETA.3 21 Increased access to quantitative microbiology
reporting may, therefore, reduce inappropriate anti-
biotic prescribing in this situation, however, an asso-
ciated decrease in sensitivity, may put some patients at
risk.
Similarly, non-quantitative BAL samples are hard to
interpret whereas culture of pathogens at >103 CFU/mL
from protected specimen brush samples or at >104
CFU/mL from BAL fluid appear to increase diagnostic
accuracy.3 22 For example, pathogens cultured at >104
CFU/mL from BAL fluid had sensitivity of 91% and spe-
cificity of 78% for the microbiological confirmation of
infection in lung tissue, which in turn correlated with
histological evidence of VAP.23
Considerable debate continues as to whether broncho-
scopic sampling is indicated for the diagnosis of
VAP.24–27 Despite evidence showing that the sensitivity
and specificity of bronchoscopic sampling are superior to
ETA, benefits in terms of patient outcomes have been
inconsistent in randomised trials. A recent meta-analysis
has not shown differences in mortality, length of stay or
antibiotic changes.28 Bronchoscopic sampling is asso-
ciated with a lower rate of positive culture among
patients with suspected VAP compared with ETA.24
Discontinuation of antibiotics in the face of negative BAL
culture has been shown to be safe and result in lower anti-
biotic use and potentially fewer antibiotic-resistant patho-
gens.29 This important potential benefit has not been
adequately evaluated in the meta-analysis and reductions
in antibiotic use, measured by an increase in antibiotic-
free days, is probably a more valid outcome measure than
mortality for future VAP trials.
Relatively little is known about the general quality of
alveolar sampling in suspected VAP. Our survey sug-
gested huge variation in sampling techniques among the
respondents who perform BAL. Guidelines for BAL gen-
erally recommend instillation of 100–240 mL of sterile
saline to ensure sampling of the alveolar space.30–32 The
median instillate described in this survey was 20 mL,
with only 9.6% (20/208) of respondents using ≥100 mL.
This suggests that many BALs may not adequately
sample alveolar tissue and may therefore be inappropri-
ate for diagnosing pneumonia. The posterior segment
of the right lower lobe is considered the most commonly
involved segment in VAP.33 Only 43.3% of respondents
who perform BAL reported sampling the right lower
lobe when CXR gives no indication of the most involved
region of the lung. Finally, respondents’ confidence in
the ability to perform BAL seemed at variance with the
fact that 24.5% described inadequate training in
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bronchoscopy and 9.5% no training at all. The overall
implication is that in a significant number of cases BAL
is unlikely to provide optimal alveolar sampling.
Together, the data pertaining to CXRs, microbio-
logical analysis and BAL suggest that an agreed optimal
approach to the diagnosis of VAP is lacking in the UK.
Few data are available to determine whether this situ-
ation is prevalent in other healthcare systems, but it
seems likely that similar circumstances will be duplicated
in at least some other countries. The clinical implica-
tions may be far-reaching. Several studies have shown
that objective evidence for VAP is only obtained between
20% and 42% of patients in whom the condition was
suspected on clinical grounds.34–36 The overall trend for
decision-making based on non-quantitative microbiology
from ETA (or from small volume ‘BAL’ which has
sampled the proximal airways) would tend to favour
false-positive diagnoses and the use of unnecessary
empirical antibiotics. Another important implication is
that the heterogeneity of diagnostic approaches will
impact on the reported incidence of VAP, significantly
undermining the value of this index as a meaningful
performance indicator in healthcare.
While our results suggest shortcomings in the diagno-
sis of VAP in current practice, several limitations must be
considered in their interpretation. In particular we
received a 23% response rate which is clearly too low to
be entirely confident that our findings are representa-
tive. The low response rate in itself may potentially
reflect a general apathy towards the subject of VAP gen-
erated by a lack of agreement with respect to the diag-
nostic and management approach.
Furthermore, in order to maintain anonymity and
survey individual consultant practice we did not request
the identity of individuals’ place of work so we are
unable to comment about differences in practice
between units. Finally, the data collected are estimates
and opinion and may not reflect an individual’s actual
practice.
CONCLUSION
There is wide variation in the diagnosis and manage-
ment of VAP among UK ICU consultants. The data pre-
sented suggest that developing a standardised approach,
incorporating increased radiological and microbiological
support and delivery of standardised BAL protocols,
might improve this situation. Until such time the use of
reported VAP rates as a performance indicator within
the UK healthcare system may be misleading.
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